New Delhi, Mar 11 (PTI) Drug firm Lupin on Friday said it has received approval from the US health regulator to market its anti-epilepsy drug Vigabatrin for Oral Solution in the American market.

The company has received approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA), Vigabatrin for Oral Solution USP (500 mg), Lupin said in a statement.

Also Read | Odisha Government To Conduct Offline Matriculation Examination From April 29.

The Mumbai-based drug firm's product is the generic equivalent of Lundbeck Pharmaceuticals' Sabril for Oral Solution.

The product will be manufactured at Lupin's manufacturing facility in Goa, it added.

Also Read | Redmi K50 Pro & Redmi K50 Pro+ With 12GB RAM Listed on Geekbench: Report.

As per IQVIA MAT December 2021 data, Vigabatrin for Oral Solution USP (500 mg) had estimated annual sales of USD 275 million (around Rs 2,100 crore) in the US.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)